Lactalis Nestlé Chilled Desserts UK will debut its Milkybar Gold White Chocolate Caramel Crème dessert, the first HFSS compliant crème dessert to market in the UK chilled desserts category
The dessert features the taste of Milkybar Gold confectionery, in a bar of creamy white chocolate and caramel flavor, at 91 calories per pot.
Christopher Pihoué, marketing manager at Lactalis Nestlé Chilled Desserts UK, described Milkybar Gold White Chocolate Caramel Crème dessert as having a unique flavor offering that will appeal to consumers”.
He added that with its calorie count and HFSS compliance, it brings a real USP in the chilled desserts aisle. The product will also capitalize on the trend towards gold chocolate product launches while attracting Milkybar confectionery fans to the chilled aisle.”
Milkybar Gold White Chocolate Caramel Crème Dessert is available in 2x65g at Tesco stores in the UK for an RRP of £1.50. A 4x65g variant will also be available beginning in July.


Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates
The American mass exodus to Canada amid Trump 2.0 has yet to materialize
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 



